Invasive candidiasis in the ICU : prophylaxis versus preemptive treatment
Candidemia/invasive candidiasis has increased in incidence over the past 15 years. Because of numerous risk factors, intensive care unit patients have a predilection for this type of infection. Most of these infections are acquired endogenously, but occasionally may result from an exogenous source. Antifungal prophylaxis and preemptive antifungal therapy have been developed to prevent candidemia/invasive candidiasis. Antifungal prophylaxis with azoles has been demonstrated to reduce candidemia, overall mortality, and attributable mortality. This strategy is also effective for the prevention of invasive fungal infection in liver transplant recipients. Preemptive treatment appears to be a more focused intervention that uses markers (eg, the presence of colonization) and serologic testing to trigger the initiation of antifungal therapy. Further developments in serologic testing are necessary to enhance the precision of selecting the patients at risk for candidemia/invasive candidiasis. The optimum agent to be used prophylactically and for preemptive therapy requires further clinical investigation.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Current infectious disease reports - 10(2008), 6 vom: 23. Nov., Seite 454-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rotstein, Coleman [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.06.2010 Date Revised 29.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM183910273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM183910273 | ||
| 003 | DE-627 | ||
| 005 | 20231223165559.0 | ||
| 007 | tu | ||
| 008 | 231223s2008 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0613.xml |
| 035 | |a (DE-627)NLM183910273 | ||
| 035 | |a (NLM)18945385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rotstein, Coleman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invasive candidiasis in the ICU |b prophylaxis versus preemptive treatment |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2010 | ||
| 500 | |a Date Revised 29.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Candidemia/invasive candidiasis has increased in incidence over the past 15 years. Because of numerous risk factors, intensive care unit patients have a predilection for this type of infection. Most of these infections are acquired endogenously, but occasionally may result from an exogenous source. Antifungal prophylaxis and preemptive antifungal therapy have been developed to prevent candidemia/invasive candidiasis. Antifungal prophylaxis with azoles has been demonstrated to reduce candidemia, overall mortality, and attributable mortality. This strategy is also effective for the prevention of invasive fungal infection in liver transplant recipients. Preemptive treatment appears to be a more focused intervention that uses markers (eg, the presence of colonization) and serologic testing to trigger the initiation of antifungal therapy. Further developments in serologic testing are necessary to enhance the precision of selecting the patients at risk for candidemia/invasive candidiasis. The optimum agent to be used prophylactically and for preemptive therapy requires further clinical investigation | ||
| 650 | 4 | |a Journal Article | |
| 773 | 0 | 8 | |i Enthalten in |t Current infectious disease reports |d 1999 |g 10(2008), 6 vom: 23. Nov., Seite 454-8 |w (DE-627)NLM110111478 |x 1523-3847 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2008 |g number:6 |g day:23 |g month:11 |g pages:454-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2008 |e 6 |b 23 |c 11 |h 454-8 | ||